2-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl)acetic acid | 215181-78-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl)acetic acid
• 英文别名: 4-[(6,7-dimethoxy-4-quinazolinyl)amino]Benzeneacetic acid；2-[4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl]acetic acid
• CAS: 215181-78-5
• 化学式: C₁₈H₁₇N₃O₄
• 分子量: 339.351
• InChiKey: YAWTYNUYRZWXPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  93.6
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-胺基-1-异丙基-1H-吡唑 、 2-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl)acetic acid 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以70%的产率得到2-[4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl]-N-(1-propan-2-ylpyrazol-4-yl)acetamide
  参考文献：
  名称：

  Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases

  摘要：

  A new series of quinoline ether inhibitors, which potently and selectively inhibit PDGFR tyrosine kinases, is described in this Letter. Compounds 23 and 33 are selective, low nanomolar inhibitors of PDGFR alpha and beta, display good pharmacokinetics in rat and dog and are active in vivo at low doses when given orally twice daily. Further evaluation of these compounds is warranted. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.074
• 作为产物：
  描述：

  对氨基苯乙酸 、 4-氯-6,7-二甲氧基喹唑啉 在 盐酸 作用下， 以 水 、 异丙醇 为溶剂， 反应 2.0h， 生成 2-(4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl)acetic acid
  参考文献：
  名称：

  Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases

  摘要：

  A new series of Quinazoline Ether Inhibitor which potently inhibits VEGFR-2 and PDGFR tyrosine kinases is described here. In vitro, pharmacokinetics and in vivo evaluations led to the selection of AZD2932. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.019

文献信息

• [EN] ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE L'ECTONUCLÉOTIDE PYROPHOSPHATASE-PHOSPHODIESTÉRASE (ENPP-1) ET UTILISATIONS DE CES DERNIERS
  申请人：MAVUPHARMA INC

  公开号：WO2019046778A1

  公开（公告）日：2019-03-07

  Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, the compounds disclosed herein are ENPP-1 inhibitors, pharmaceutical compositions, and methods for the treatment of cancer or a viral infection.

  本文揭示了一种增强和促进体内I型干扰素产生的方法和化合物。在某些实施例中，本文所披露的化合物是ENPP-1抑制剂，药物组合物，以及用于治疗癌症或病毒感染的方法。
• Contrast agents
  申请人：AMERSHAM HEALTH AS

  公开号：US20040009122A1

  公开（公告）日：2004-01-15

  The invention provides a composition of matter of the formula (I): V-L-R, where V is a vector moiety having affinity for an angiogenesis-related endothelias cell receptor, L is a linker moiety or a bond and R is a detectable moiety, characterised in that V is a non-peptidic organic group, or V is peptidic and R is a macromolecular or particulate species providing a multiplicity of labels detectable in in vivo imaging.

  本发明提供了一种物质组成式（I）的组合物：V-L-R，其中V是具有亲和力的向量基团，用于与血管生成相关的内皮细胞受体结合，L是连接基团或键，R是可检测的基团，其特征在于V是非肽有机基团，或者V是肽基团且R是提供在体内成像中可检测的多重标记的大分子或颗粒物种。
• Method of imaging
  申请人：Amersham Health AS

  公开号：EP1442751A1

  公开（公告）日：2004-08-04

  The invention provides a method of generating an image of an animate human or non-human animal subject previously administered with a contrast agent involving generating an image of at least a part of said subject to which said contrast agent has distributed, characterised in that said contrast agent is a composition of matter of formula I         V - L - R     (I) where V is a vector moiety having affinity for an angiogenesis-related endothelial cell receptor, L is a linker moiety or a bond and R is a detectable moiety, characterised in that V is a non-peptidic organic group, or V is peptidic and R is a macromolecular or particulate species providing a multiplicity of labels detectable in in vivo imaging.

  本发明提供了一种生成先前施用过造影剂的有生命的人类或非人类动物主体图像的方法，该方法涉及生成所述造影剂分布到的所述主体的至少一部分的图像，其特征在于所述造影剂是式 I 的物质组合物 V - L - R (I) 其中 V 是对血管生成相关内皮细胞受体具有亲和力的载体分子，L 是连接分子或键，R 是可检测分子，其特征在于 V 是非肽有机基团，或 V 是肽基，R 是大分子或微粒，可提供在体内成像中可检测的多重标签。
• CONTRAST AGENTS TARGETTING RECEPTORS ASSOCIATED WITH ANGIOGENESIS
  申请人：Amersham Health AS

  公开号：EP0977600B1

  公开（公告）日：2004-06-30
• Diagnostic imaging technique
  申请人：GE Healthcare AS

  公开号：EP1442751B1

  公开（公告）日：2007-06-20